Nanjing Synnocare Pharmaceutical Technology Co. Ltd. and Shanghai Synnocare Biopharmaceuticals Co. Ltd. have patented ATP-dependent RNA helicase A (DHX9) inhibitors with potential for use in the treatment of cancer, autoimmune and viral infections.

F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized pyridone carboxamide-derived compounds acting as soluble epoxide hydrolase inhibitors. They are reported to be useful for the treatment of diabetic retinopathy, neuropathic pain and neurodegenerative diseases.

Work at Shanghai 3D Medicines Laboratory Co. Ltd. has led to the discovery of new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers designed for use in the treatment of pain.

Pfizer Inc. has identified 4-{4-[(1-{[4-(propan-2-yl)phenyl]carbamoyl)-D-prolyl)amino]cyclohexyl}benzoic acid derivatives acting as gastric inhibitory polypeptide receptor (GIPR) antagonists. As such, they are described as potentially useful for the treatment of type 2 diabetes and obesity.

Shionogi & Co. Ltd. has disclosed heterocyclic derivatives characterized as reverse transcriptase/ribonuclease H (HIV-1) inhibitors for potential use in the treatment of HIV infection.

Scientists from Fu Wai Hospital of the Chinese Academy of Medical Sciences and Shenzhen Bay Laboratory have divulged cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) inhibitors. They are reported to be useful for the treatment of autoimmune diseases, cancer, neurological disorder, diabetes, inflammatory bowel disease, pulmonary fibrosis, psoriasis and arthritis, among others.

Shanghai Deep Potential Technology Co. Ltd. has discovered serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer.

Shanghai Chempartner Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising HER2 (erbB2) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to eribulin through a linker reported to be useful for the treatment of cancer.

Jiangxi Kerui Pharmaceutical Co. Ltd. has patented potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators. They are reported to be useful for the treatment of anxiety disorders, depression, pain, focal seizures and tonic clonic epilepsy.

Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have disclosed tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors. They are reported to be useful for the treatment of cancer, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), obesity and diabetes.